These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30201948)

  • 1. The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in Multiple Myeloma and its Prognostic Significance.
    Xiong T; Luo Z
    Med Sci Monit; 2018 Sep; 24():6340-6348. PubMed ID: 30201948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPEB2 enhances cell growth and angiogenesis by upregulating ARPC5 mRNA stability in multiple myeloma.
    Zeng P; Wang F; Long X; Cao Y; Wen F; Li J; Luo Z
    J Orthop Surg Res; 2023 May; 18(1):384. PubMed ID: 37231521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma.
    Kinoshita T; Nohata N; Watanabe-Takano H; Yoshino H; Hidaka H; Fujimura L; Fuse M; Yamasaki T; Enokida H; Nakagawa M; Hanazawa T; Okamoto Y; Seki N
    Int J Oncol; 2012 Jun; 40(6):1770-8. PubMed ID: 22378351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMSA-1 expression pattern in multiple myeloma and its clinical significance.
    Meng S; Lu C; Zhang W; Shen W; Wei Y; Su D; Zhou F
    Clin Exp Med; 2016 Nov; 16(4):599-609. PubMed ID: 26493349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    Ming Y; Luo C; Ji B; Cheng J
    BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and Clinical Significance of NAMPT in Bone Marrow of Patients with Multiple Myeloma].
    Wang YR; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1739-1744. PubMed ID: 38071054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
    Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
    Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of interleukin 16 in multiple myeloma.
    Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
    J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.
    Jurisić V; Colović M
    Med Oncol; 2002; 19(3):133-9. PubMed ID: 12482123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
    Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
    Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
    Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
    Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
    Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.